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Final height in congenital 
adrenal hyperplasia: the 
dilemma of hypercortisolism 
versus hyperandrogenism
Altura final na hiperplasia suprarrenal congênita: o dilema 
do hipercortisolismo versus hiperandrogenismo
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ABSTRACT
Objective: The purpose of this study was to identify factors that might interfere with reaching 
the final height in patients with 21-hydroxylase deficiency (21-OHD). Subjects and methods: 
Thirty-one patients with classical 21-OHD who reached their FH in our Institution were eva-
luated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the 
standard height for the population, and (3) the hydrocortisone treatment schedule. Results: 
The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses 
used throughout the period of study. Patients who reached FH within the normal population 
range were those who received lower doses of hydrocortisone, as compared to those whose 
FH remained below -2 SDS. Conclusion: We conclude that careful treatment adjustments have 
a major influence on growth of children with CAH, and that the dose range for hydrocortisone 
replacement that does not lead to side effects is relatively narrow. The better height outcome 
was achieved in 21-OHD patients who received lower doses of hydrocortisone. Arq Bras Endocrinol 
Metab. 2013;57(2):126-31
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RESUMO
Objetivo: O objetivo do estudo foi a identificação de fatores que podem interferir na aquisição 
de altura final de pacientes com a deficiência de 21-hidroxilase (21OHD). Sujeitos e métodos: 
A altura final (escore Z: FHZ) de 31 pacientes com a forma clássica da 21OHD, acompanhados 
em nossa instituição, foi comparada com: (1) a altura alvo, (2) o padrão de referência para a po-
pulação, e (3) a dose de hidrocortisona durante o acompanhamento. Resultados: Observou-se 
correlação negativa significativa entre o FHZ de -2,13 ± 1,11 e as doses de hidrocortisona utiliza-
das durante o período de estudo. Os pacientes que atingiram altura final dentro do padrão de 
referência para a população usaram doses mais baixas de hidrocortisona quando comparados 
àqueles que permaneceram abaixo de -2 DP. Conclusão: O cuidado nos ajustes das doses du-
rante o tratamento da 21OHD tem grande influência sobre o crescimento das crianças. A faixa 
de variação da dose de reposição da hidrocortisona que não causa efeitos colaterais é relativa-
mente estreita. O melhor resultado estatural foi observado nos pacientes com 21OHD tratados 
com doses mais baixas de hidrocortisona. Arq Bras Endocrinol Metab. 2013;57(2):126-31
Descritores
Hiperplasia suprarrenal congênita; esteroide 21-hidroxilase; corticosteroides; hidrocortisona; estatura
1 Division of Pediatric 
Endocrinology, Department of 
Pediatrics, Universidade Federal 
de Minas Gerais (UFMG), 
Belo Horizonte, MG, Brazil
2 Endocrinology Department, 
Universidade Federal de São Paulo 
(Unifesp), Sao Paulo, SP, Brazil
Correspondence to: 
Ivani Novato Silva
Divisão de Endocrinologia
Infantil e do Adolescente,
Departamento de Pediatria,
Faculdade de Medicina,
Hospital das Clínicas,
Universidade Federal de Minas Gerais 
Av. Alfredo Balena, 190, sala 267 
30130-100 – Belo Horizonte, MG, 
Brasil
ivanins@medicina.ufmg.br
Received on Ago/16/2012
Accepted on Sept/22/2012
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
127Arq Bras Endocrinol Metab. 2013;57/2
INTRODUCTION
C ongenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is a com-
mon autosomal recessive hereditary disorder. Impair-
ment of cortisol synthesis leads to excessive ACTH 
stimulation of the adrenal cortex, resulting in hyperan-
drogenism (1).
Treatment of classic 21-OHD consists of replace-
ment doses of gluco- (GC) and mineralocorticoids, 
aiming to reduce excess androgen, and to allow ade-
quate linear growth. However, several series report 
that growth in these children is below expectation, as 
compared with both the reference population and the 
target height (TH) (2). The reasons for the inadequate 
growth and impairment of the final height (FH) are not 
completely understood. A major cause is the difficulty 
in accomplishing a fine balance between inhibition of 
excess androgen production – which accelerates bone 
maturation –, and adequate GC replacement itself – 
which even at slightly supraphysiologic doses can be 
deleterious to growth. 
In this paper, we present the results of FH in pa-
tients with CAH due to 21-OHD followed up for ap-
proximately 10 years in a single institution, and the va-
riables related to this outcome. 
SUBJECTS AND METHODS
All patients with CAH due to classic 21-OHD follo-
wed up at the Pediatric Endocrinology Division of the 
University Hospital (HC-UFMG) in Belo Horizonte, 
Brazil, who had achieved the FH by 2005 were evalua-
ted. The study was approved by the Research Ethics 
Committee of the Institution. After signing the in-
formed consent term, patients and their parents were 
examined by a single researcher in a pre-scheduled ap-
pointment. Data obtained from the beginning of the 
patient’s follow-up at the HC-UFMG were retrieved 
from the medical records. Patients with other diseases, 
or those receiving drugs that could affect linear growth 
were excluded. Twenty-five of the 31 patients (80%) 
have been regularly followed up from diagnosis to FH. 
CAH diagnosis was based on the presence of am-
biguous genitalia, which occurred in all girls, and ma-
crogenitossomia (in boys), associated with increased 
17OHP and androgens. Salt wasting (SW) was establi-
shed according to a report of salt losing crisis, in addi-
tion to the need of fludrocortisone acetate to maintain 
normal electrolyte levels. Male patients with the simple 
virilizing form (SV) presented incomplete precocious 
puberty before four years of chronological age (CA) 
with acceleration of bone age (BA).
FH was characterized by growth velocity less than 
0.5 cm per year, and bone age greater than 15 for girls 
and 17 years for boys (3). All bone ages were interpre-
ted by an experienced radiologist by means of X-rays 
of the left hand and wrist, using the Greulich and Pyle 
method (4). 
Twenty-six patients received three doses of hydro-
cortisone daily (half in the morning). The doses were 
not uniform since the study included patients who 
initiated treatment before or after 1995, when the re-
commended treatment schedule was modified after the 
study of Silva and cols. (5), switching from 15-25 mg/m² 
BSA/day to 10-15 mg/m² BSA/day. In an attempt to 
improve compliance with the treatment, five patients 
received long-acting GC (four received prednisone and 
one, dexamethasone). In order to have a uniform analy-
sis, long-acting GCs were transformed into equivalent 
doses of hydrocortisone, as follows: hydrocortisone 30 
mg = prednisone 6 mg = dexamethasone 0.375 mg (6), 
according to body surface area. Fludrocortisone aceta-
te at 0.05 to 0.2 mg per day was used as replacement 
mineralocorticoid therapy. None of the patients un-
derwent puberty block.
Due to the wide fluctuation of 17OHP and andros-
tenedione plasma concentrations, patients were subdi-
vided into two groups for laboratory evaluation: those 
presenting less than 50% of the results greater than six-
-fold the maximum reference value, considered as satis-
factory controls (group 1), and those presenting more 
than 50% above these values, considered as inadequate 
controls (group 2). Complete normalization of lab re-
sults was not considered a primary therapeutic target 
during patient follow-up. The adequacy of mineralo-
corticoid replacement was assessed by absence of clini-
cal signs and maintenance of normal electrolyte levels. 
Poor treatment compliance was considered whene-
ver this information was specified in the medical records. 
Statistical analysis
Z scores for height were calculated at baseline, at two 
years of CA, and at the FH (FHZ), using the National 
Center for Height Statistics (NCHS) reference (7); Z 
scores for bone age were also calculated at the same 
moments, and for the TH. All FH values were adjusted 
for sex, the CAH form, and hormonal parameters. FH 
of patients who used higher and lower than 15 mg/m² 
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BSA/day mean hydrocortisone dose were compared, 
as well as the GC doses of those who did or did not 
reach the FH within the normal range for the overall 
population (> -2 SD scores). Comparisons within the 
same group were performed by the Student’s t test 
for paired samples, whereas comparisons between di-
fferent groups were done by analysis of variance or by 
the Kruskal-Wallis non-parametric test, when indica-
ted. Simple regression analysis was used to correlate the 
hydrocortisone dose (median of the whole follow-up) 
with FH. Epinfo software version 6.0 was used for all 
the statistical analysis, whereas the Epinutri program 
was used for anthropometric evaluation. Rejection of 
the null hypothesis was set at 5% (p < 0.05).
RESULTS
Table 1 shows the clinical characteristics of the 31 pa-
tients with 21-OHD studied: 26 (84%) were female 
and 17 (54.8%) were salt-wasters. Median age at the 
beginning of follow-up was 2 yrs. and 3 mo. (ranging 
from newborn to 8 yrs. and 3 mo.). Mean follow-up 
until the final height was 10.3 ± 4.2 yrs. Mean FHZ of 
the whole group was -2.13 ± 1.11. There were no sig-
nificant differences between the final heights and sex, 
compliance with treatment, the clinical form of CAH, 
and hormone control. The mean FHZ of 20 patients 
with known TH was -1.97 ± 1.15. There was a significant 
impairment of FHZ compared with the target height Z 
(p = 0.022), demonstrating that these children did not 
reach their genetic potential. 
The median dose of hydrocortisone used was 13.7 
mg/m² BSA/day (ranging from 10.9 to 40 mg/m² 
BSA/day). A moderately significant negative correla-
tion (r = -0.48, r2 = 0.23, p < 0.05) was observed be-
tween the doses of hydrocortisone and FH. Group 1 
used a significantly higher mean hydrocortisone dose 
(22.6 ± 8.2 mg/m²/day) than group 2 (13.1 ± 1.1 
mg/m²/day). Patients who used doses lower than 15 
mg/m² BSA/day reached a significantly higher mean 
FHZ (-1.83 ± 1.00) than those who used doses hi-
gher than 15 mg/m² BSA/day (FHZ: -2.68 ± 1.14; 
p = 0.038). On the other hand, patients who reached 
normal FH (n = 10), defined as > -2SD of the mean 
height for the overall population, used a significant 
(p = 0.035) lower median dose of hydrocortisone 
(13.05  mg/m² BSA/day) than those (n = 18) who 
remained shorter (median HC dose: 14.85 mg/m² 
BSA/day) (Table 2).
Table 1. Clinical characteristics of 31 patients with CAH due to classic 
21-OHD who reached their final height 
n (%)
Gender
Male 5 (16) 
Female 26 (84)
Clinical presentation
Salt-wasting 17 (54.8)
Virilizing form 14 (45.2)
Age at diagnosis (yrs.)
Median 2.3
Range 1 mo. – 8 yrs. 
Hydrocortisone dose (mg/m²/d)
Median 13.7
Range 10.9 – 40
Anthropometric data (Z-score) 
Final height -2.13 ± 1.11
Target height (n = 20) -1.25 ± 0.75
Table 2. Hydrocortisone doses and final heights of 31 patients with CAH 
due to classic 21-OHD who reached their final height
Hydrocortisone dose (mg/m²/d) Final height (Z-score) p
Median (n = 31)
13.7 (10.9-40)
13.05  (n = 10) 
14.85  (n = 18)
-2.13 ± 1.11
> -2SD 
< -2SD 
< 0.05*
0.035
Mean
Group 1 (n = 11) 
22.6 ± 8.2
Group 2 (n = 20) 
13.1 ± 1.1
-2.68 ± 1.14
-1.83 ± 1.00
0.038
* Simple linear regression.
Final height in congenital adrenal hyperplasia
Seventeen children were up to 2 years and 4 months 
when treatment was initiated; mean follow-up until 
FH was 12.5 ± 1.76 years, and the median daily HC 
dose during follow-up was 15.49 mg/m² BSA. Mean 
FHZ was -2.05 ± 0.98 and pretreatment height Z 
score was -0.60 ± 2.35, disclosing a statistically sig-
nificant (p = 0.014) height loss during the growth 
period, although no difference was observed when 
the FH scores were compared with height scores at 
two years of CA age (-1.37 ± 2.3; p = 0.21). Twelve 
patients with known target heights presented mean 
FHZ of -1.73 ± 0.98, which was not significantly di-
fferent from their target height of -1.24 ± 0.81 (p = 
0.096), demonstrating that they reached their genetic 
potential. 
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DISCUSSION
Despite recent developments in CAH, several issues 
related to patient growth and final height remain un-
solved. Most recent series have shown that affected pa-
tients have blunted final height, as compared with their 
targets. In a meta-analysis involving 561 patients, Eu-
gster and cols. found mean FH (-1.37 SD) higher than 
previously reported (-2.0 SD), but still lower than the 
values found in the overall population (8). Another me-
ta-analysis including 35 eligible studies showed that the 
final height of CAH patients (-1.38 SD) is lower than 
the population norm, and is lower than expected given 
parental height (9). Diagnosis up to one year of CA 
and good treatment compliance had a positive influen-
ce in FH (8-10); however, the reasons for this shortfall 
are not fully known. It is believed that treatment inter-
ference is a major cause, in addition to the influence 
of excessive androgen production that occurs despite 
the best possible control. Recent data point out to the 
harm ful impact of glucocorticoid treatment in FH ou-
tcomes (11), and other reports suggest better outcomes 
after the use of lower HC doses (12-13). Alternative 
treatments, such as the use of growth hormone associa-
ted to puberty inhibitors, in addition to anti-estrogen 
therapy, were used in an attempt to improve height 
prognosis in these patients (14-17). However, the high 
cost, greater likelihood of non-compliance with multi-
-drug regimens, and the associated side effects, render 
these alternatives little attractive. Nonetheless, an ideal 
corticosteroid replacement schedule has not yet been 
devised. Baseline cortisol secretion is estimated at 5.7 
to 10 mg⁄m² BSA⁄24h in normal individuals (18), but 
physiological doses of GC are apparently insufficient to 
normalize ACTH in the setting of 21OH deficiency. 
Even if ACTH normalization is attained, androgen se-
cretion not necessarily normalizes, since the shunt in-
duced by the enzymatic block increases the proportion 
of intermediate steroids in the androgen pathway, even 
with reduced cortical activity. As a result, patients with 
21OHD would present, during treatment, either nor-
mal to low androgen concentrations with hypercortiso-
lism, or adequate cortisol concentrations but increased 
androgen levels, or still, mild hypercortisolism and mild 
hyperandrogenism (16). This would be the core of dis-
cussions regarding conventional treatment in which 
all three situations may have a negative effect on gro-
wth. Therefore, the key issue regarding treatment and 
growth in 21-OHD is keeping a fine balance between 
exogenous hypercortisolism and endogenous hyperan-
drogenism, both playing a reciprocal negative influence 
on final height. 
The mechanism by which glucocorticoid therapy in-
terferes with growth is complex and multifactorial. Re-
latively slight supraphysiologic levels may be enough to 
blunt growth velocity. In a previous study, we have al-
ready reported in a group of CAH children that a short 
period of daily hydrocortisone doses of 15 mg/m² was 
associated to better growth velocity when compared 
to another short period using 25 mg/m² BSA, despite 
the limited inhibition of androgen production. At that 
time, we were concerned whether the high concentra-
tions of androgens would cause advanced bone age, 
thus offsetting the benefit of the lower doses of GC 
upon FH (5). Others also observed a negative effect of 
a hydrocortisone dose of 17.64 ± 3.60 mg/m² BSA/
day on growth, preventing children from achieving 
their genetic potential (19). In the present study, an 
improvement in FH was observed in patients receiving 
the median hydrocortisone dose of 13.05, as compared 
with the 14.85 mg/m² BSA/day dose, suggesting that 
the margin for dose adjustments without producing 
side effects is relatively narrow. 
In addition, the negative effect of the hydrocortiso-
ne dose seems to be greater according to the period of 
life in which this dose is administered. Studies evalua-
ting GC effect during childhood evidenced a negative 
influence of the daily dose of GC upon growth velocity 
and FH in children up to one or two years of CA and 
in prepubertal children (11,20-23). Similar to Manoli 
and cols. who showed a positive correlation of FHZ 
and height at 2 years of age in salt-losing patients (21), 
the present study corroborates that height loss occurs 
mainly within the first two years of life. In addition, 
some reports showed that FH was greater in patients 
with early treatment, up to 20 months (24) and before 
3 years of CA (20), although these data are controver-
sial among the authors (3,23). In this study, a group 
of patients who initiated treatment early reached their 
TH. There is now some evidence that, with appropriate 
clinical management, children can achieve their genetic 
potential (2,13,21).
An increased risk of developing obesity (2) is another 
possible consequence of hypercortisolism in children 
with CAH. In a recent study, the presence of increased 
fat mass with abdominal and truncal fat distribution su-
ggests the possibility of hypercortisolism in the patients 
(25). It was also stated that body fatness is a problem 
starting in early childhood in CAH patients, despite 
Final height in congenital adrenal hyperplasia
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“physiological” corticosteroid doses; thus, further re-
finement of the glucocorticoid replacement regimens, 
as well as measures to change lifestyle are needed (26).
Conversely, minimizing hyperandrogenism is not an 
easy task. Our study showed that the use of hydrocor-
tisone doses closer to the physiological requirements 
could lead to more appropriate growth, regardless of 
hormonal control, as also found by others. Excessive 
androgen exposure seems to affect the growth periods in 
different ways (19). The report of untreated SV pa-
tients who did not undergo growth acceleration up 
to 18 months of age (27) is in line with the report of 
relative resistance to androgens in growth at this age 
(28), and with the finding of an alternative backdoor 
pathway existing in the androgen biosynthesis of 21-
OHD patients, which explains divergences between 
virilization and androgen levels seen in clinical prac-
tice (29); likewise the same happens during puberty, 
a period with physiological increase of androgens (6). 
Therefore, it seems desirable to avoid higher hydrocor-
tisone doses, mainly in these periods. The use of long-
-acting glucocorticoids that could efficiently suppress 
adrenal androgen production presents great potential 
for overtreatment, and should be considered with ex-
treme caution (30). 
Besides the influence of androgens in growth of chil-
dren with CAH, recent data have alerted practitioners 
to other possible consequences of hyperandrogenism 
in these patients. It has been suggested that CAH pa-
tients develop an unfavorable cardiovascular risk profile 
either because of the existence of hyperandrogenism 
in undertreated patients, or because of the iatrogenic 
hypercortisolism consequent to excess glucocorticoid 
(31,32). Hyperandrogenism, an independent risk fac-
tor for hyperinsulinism, and iatrogenic hypercortiso-
lism could both contribute to hyperinsulinism and 
insulin resistance in these patients (33-35). Therefore, 
there are still several unresolved questions in respect to 
the persistent hyperandrogenism in these patients. 
In conclusion, our results confirm that the use of 
hydrocortisone doses closer to physiological require-
ments is able to lead adequate linear growth and final 
heights within expected ranges. Patients receiving early 
treatment reached the target height regardless of achie-
ving an optimal control of hyperandrogenism. Lower 
doses of hydrocortisone and early initiation of treat-
ment were associated to better FH. In view of these 
results, we believe that, in patients treated for CAH, 
hypercortisolism is more harmful to growth than hype-
randrogenism. However, additional studies are neces-
sary to fully appreciate the possible consequences of 
long-term poor androgen control. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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